FDA Approves Pill Version of Wegovy: What You Need to Know

The direct primary care model, which previously represented a niche in the healthcare sector, has seen significant growth, with thousands of practices now operating across the United States. This model allows patients to pay a monthly subscription fee directly to their healthcare providers, eliminating the need for insurance and facilitating easier access to care, longer appointment times, and consistent treatment from the same physician.

Music icon Barry Manilow has announced that he has been diagnosed with lung cancer, revealing that doctors found a cancerous spot on his left lung that requires surgical removal. This diagnosis has led to the postponement of nine shows originally scheduled for January, as the 82-year-old artist will need time to recover from the surgery.

U.S. regulators have approved Wegovy in pill form, marking a significant advancement as it becomes the first daily oral medication for weight loss, developed by Novo Nordisk. This approval is seen as a pivotal moment in the treatment of obesity, providing a new option for patients seeking effective weight management solutions.

Novo Nordisk shares surged following the FDA's approval of a pill version of Wegovy, a weight-loss medication, marking a significant milestone for the company. This approval provides an oral alternative for patients seeking obesity management, enhancing accessibility to the treatment.

The FDA has approved the first oral formulation of Wegovy, a weight-loss medication developed by Novo Nordisk, which is set to be available in the U.S. at a cash price of $149 per month starting in the new year. This approval marks a significant milestone in the pharmaceutical industry, providing a new option for patients managing obesity.